CSPC Pharmaceutical Group (HKG:1093) officially began a phase 1 clinical trial of SYH2056 tablets for the treatment of depression.
The trial in China will study the safety, tolerability, and pharmacokinetic profile of the product, as well as the food effect in healthy participants, according to a Tuesday filing with the Hong Kong bourse.